CA180-034 final study results: Seven-year (yr) follow-up of chronic-phase chronic myeloid leukemia (CML-CP) patients (pts) with imatinib resistance or -intolerance receiving dasatinib, a 2nd-generation BCR-ABL tyrosine kinase inhibitor (TKI)
ONCOLOGY RESEARCH AND TREATMENT（2015）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要